In this interview with The Dales Report, InMed CEO Eric A. Adams talks about how the scalability of synthesized rare cannabinoids will make them more affordable.
Read the article and watch the full video at The Dales Report.
In this interview with The Dales Report, InMed CEO Eric A. Adams talks about how the scalability of synthesized rare cannabinoids will make them more affordable.
Read the article and watch the full video at The Dales Report.
In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s
There have been major advances in Alzheimer’s disease research and development in the past two years alone. What are those breakthroughs and what’s in development
In this video, InMed’s CEO, Eric A. Adams, explains the neuritogenesis process and how this process is essential for neuronal signaling and healthy brain functioning.
© Copyright 2024 InMed Pharmaceuticals Inc.
"*" indicates required fields